Abstract
causative strain in the majority of cases in Europe, and a high degree of clonal relatedness has been found with genome sequencing techniques. [8] [9] [10] [11] It is speculated that the LGV epidemic among MSM in Europe caused by the L2b subvariant may have been imported to Europe from the United States by the end of the previous century via the global highly interconnected network of sexual contacts among MSM. 12, 13 Endemic acquired cases of LGV in heterosexuals are extremely rare in Europe, and there is no evidence of transmission of LGV within the European heterosexual population. [14] [15] [16] [17] Aetiology and transmission
• Causative pathogen: Chlamydia trachomatis genovars L1, L2
and L3. Subvariants have been described such as L2b, currently frequently spreading among MSM. Confusion in identifying new and emergent strains stress the importance of adhering stringently to the nomenclature rules developed by the International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of the Chlamydiae. 18 • Heterosexual transmission of the strains found in MSM is extremely rare. [14] [15] [16] • In contrast to genovars A-K, which remain confined to the mucosa, genovar L strains are invasive and can disseminate via underlying connective tissue and spread to regional lymph nodes.
• Mixed infections with genovar L plus D-K strains 19 and mutant strains with recombinant DNA from L plus D-K strains 20 have been described with unknown clinical relevance.
• Worldwide, LGV is thought to account for 2-10% of genital ulcerative disease in areas such as South-East Asia and Africa, although these figures are based on older studies. 21 In many high income countries, LGV is endemic among MSM, mainly those co-infected with HIV. 22 • Neither the degree of infectiousness nor the reservoir of disease has been accurately defined. Transmission has been attributed largely to asymptomatic carriers.
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• Transmission in the MSM population can partially be explained via anogenital contact. Since the ratio of genital vs. anorectal LGV infections has been shown to be 1 in 15 in some settings, 4 other modes of transmission are suspected. 24 
Clinical features
• In MSM, about 25% of the anorectal LGV infections are asymptomatic. 3, 23, 25 • Depending on the site of inoculation, LGV can cause inguinal disease (after inoculation of the genitalia or anal area), or the anorectal syndrome (after inoculation via the rectum).
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• The incubation period is 1-4 weeks, after which three subsequent stages can follow: a primary ulcerative stage, a secondary stage with loco-regional dissemination with buboes and fistulae, and a tertiary more complicated fibrotic stage with irreversible lymphedema.
21
Genital symptoms
• Primary stage: Initially, a small painless papule or pustule appears that may erode to form a small herpetiform ulcer. Usually, it heals within 1 week and often remains unnoticed, but may present as a chancre also. Depending on the inoculation site, mucopurulent discharge may be present, affecting the rectum or, rarely, the urethra or the cervix. 21, 26 • Secondary stage: 'inguinal stage' -begins 2-6 weeks after onset of primary lesion, and causes painful inguino-femoral lymphadenopathy. Typically, this produces unilateral enlargement, inflammation, suppuration and abscesses. These 'buboes' may become fluctuant and rupture in one third of patients. Some patients develop the 'groove sign', which results from enlargement of the inguinal nodes above, and the femoral nodes below the inguinal ligament (Poupart's ligament).
21,26
• In low-and middle-income countries, inguino-femoral lymphadenopathy is the typical presentation of LGV. It is mainly seen in male patients.
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• Genital infections are rarely seen in MSM. 4 Anorectal symptoms
• Proctitis is the main manifestation of infection in the current LGV epidemic among MSM. It can be characterized by severe symptoms of anorectal pain, haemopurulent discharge and bleeding per rectum; tenesmus and constipation are also seen due to the mucosal and perirectal oedema. Yet, the severity and extent of symptoms varies between patients. Anoscopic examination may reveal a distal granular or haemorrhagic proctitis with purulent exudate, mucosal ulceration and tumorous masses.
LGV proctitis is usually not accompanied by inguino-femoral lymphadenopathy; however, radiological imaging may demonstrate pelvic and lower abdominal lymph node involvement.
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• Lymphogranuloma venereum proctitis can mimic chronic inflammatory bowel diseases like Crohn's disease, both clinically and in the histopathological features. 27, 28 • In women, usually the rectum, upper vagina, cervix, or urethra are involved. These body locations drain to the deep iliac or perirectal nodes resulting in lower abdominal pain or lower back pain. Inguino-femoral lymphadenopathy is often absent.
21,26
Physical signs
• Reactive inflammatory responses can result in constitutional symptoms, such as low-grade fever, chills, malaise, myalgia, arthralgia.
• Pharyngeal infections can cause submandibular and cervical lymphadenopathy, although these are rare. 29 
Complications
• The tertiary stage of disease in LGV is often called the 'anogenitorectal syndrome' and is more often present in women. Patients initially develop proctocolitis followed by perirectal abscess, fistulas, strictures and stenosis of the rectum, possibly leading to 'lymphorrhoids' (haemorrhoid-like swellings of obstructed rectal lymphatic tissue). Without treatment, chronic progressive lymphangitis leads to chronic oedema and sclerosing fibrosis, resulting in strictures and fistulas of the involved region, which can ultimately lead to elephantiasis, esthiomene (the chronic ulcerative disease of the external female genitalia) 30 and the frozen pelvis syndrome. 21, 26 If left untreated, LGV proctitis can lead to rectal strictures, with subsequent sequelae of soiling, pain, constipation and the possible development of mega colon.
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• Rare reactive complications include sexually acquired reactive arthritis, aseptic cardiac involvement, meningitis and ocular inflammatory disease.
21,26
• Rare septic complications include arthritis, pneumonitis or (peri)hepatitis.

Diagnosis
Who should be tested?
• Lymphogranuloma venereum testing is not available in all settings, and recommendations on who to test can therefore be limited by availability. Ideally, appropriate LGV routine molecular diagnostics should be available in all European countries, which could also be centralized at some national reference, or similar type of expert laboratory.
• Irrespective of symptoms, all MSM with a C. trachomatis
positive anorectal sample should be tested for LGV.
• Contacts of confirmed LGV index cases.
• Patients with symptoms suspected of having LGV.
• According to local or national policies, priority should be given to HIV-positive MSM, or MSM who are eligible for HIV Pre-Exposure Prophylaxis (PrEP) (1,A).
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• Other C. trachomatis positive sites (urethra/urine/pharynx) can be tested for LGV if symptoms persist despite having used recommended treatment options (2,D).
When should be tested?
• Lymphogranuloma venereum testing should be performed on a C. trachomatis nucleic acid amplification test (NAAT) positive sample and considered in patients with signs of proctitis/proctocolitis, femoro-inguinal lymphadenopathy or bubo's, and/or (a history of) genital ulcers. 35, 36 • In asymptomatic MSM, a window phase of at least 2 weeks after exposure should be considered (2,D).
Which test should be used?
• The diagnosis of LGV should be confirmed by the detection of genovar-specific C. trachomatis DNA.
• For sensitive and specific detection of LGV genovar (L1, L2 and L3, including subvariant)-specific C. trachomatis DNA, laboratories are currently recommended to use a two-step procedure (1,B): General considerations
• For clinical management, identification of the LGV genovar should be performed in a timely manner (preferably within 1 week).
• In the absence of thoroughly validated commercially available LGV genovar-specific NAATs, it is of utmost importance that laboratories performing LGV diagnostics implement only carefully validated and quality assured laboratory-developed NAATs and/or perform a strict validation for local requirements and subsequently use the NAAT with appropriate internal and external quality controls.
Alternative diagnostic methods
• In the absence of LGV genovar-specific C. trachomatis NAAT, a presumptive LGV diagnosis can be made using validated and quality-assured Chlamydia genus-specific serological assays. A high antibody titre (particularly IgA anti-MOMP antibodies) in a patient with symptoms suggestive of LGV supports the diagnosis. 31, 33, 34, [47] [48] [49] Importantly, a low titre does not exclude LGV, nor does a high titre in a patient without LGV symptomatology confirm
LGV infection. 25, 31, [33] [34] [35] 38, 49 It should be noted that the diagnostic sensitivity and specificity of serology are suboptimal, serologic test interpretation for LGV is not standardized, tests have not been appropriately validated for clinical proctitis/proctocolitis presentations, comparative data between different serologic tests are lacking, and serology cannot necessarily distinguish past from current LGV infection (1,B).
• Isolation of C. trachomatis in cell culture with subsequent specific detection of the LGV genovar can be used for diagnosis but the method has a suboptimal sensitivity, 21 is labour intensive, expensive, rarely available and now outdated.
• The identification of rectal polymorphonuclear leucocytes (PMNLs) in rectal swabs from symptomatic patients is predictive of LGV proctitis, especially in HIV-positive MSM. A PMNL number of >10 35 and >20 31 per high-power field both show to be significant, however, the sensitivity and especially specificity of this measurement can be suboptimal (1,B).
Which specimens can be used to diagnose LGV?
Samples include: (i) swab of ulcer base, or exudate from primary anogenital lesions; (ii) rectal mucosal specimens (swabs or biopsies, ideally collected from the mucosal lining under proctoscopic vision, but also self-collected rectal swabs in asymptomatic MSM); (iii) lymph node or bubo aspirates using a 21-gauge needle after topical disinfection (in suspected cases of inguinal LGV); iv) urethral swab or first-catch urine specimen when LGV is suspected; and (v) pharyngeal swabs from MSM and women exposed at those sites.
Management
• The prevalence of HIV among MSM with LGV ranges from 67% to 100% in 13 descriptive studies. There is a significant association between HIV and LGV (odds ratio, 8.19, 95% CI, 4.68-14.33) (1,A). 22, 50 Moreover, hepatitis C is associated with LGV in the current epidemic among MSM.
51-53
• Therefore, tests for other STIs (at a minimum syphilis and gonorrhoea), including HIV (if not already known HIVpositive), hepatitis B and hepatitis C should be offered before starting therapy (1,B).
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• If no LGV diagnostic test is readily available, consider LGV treatment in case of severe proctitis in MSM with a C. trachomatis positive anorectal test result (2,C).
Information, explanation and advice for the patient • In anorectal disease, symptoms should resolve within 1-2 weeks of commencing antibiotic therapy (2,C).
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• In inguinal disease, symptoms might persist for many weeks and follow-up visits should be implemented (2,C).
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• Patients should abstain from any sexual contact until they have completed therapy (2,D).
• Screening for STIs (at a minimum syphilis and gonorrhoea), including HIV (if not already known HIV-positive), hepatitis B and hepatitis C should be advised during a follow-up visit 3 months after an LGV diagnosis to cover window periods and exclude reinfections (2,D). 54 
Therapy
Which antibiotic should be used to treat symptomatic LGV?
• Doxycycline 100 mg twice a day orally for 21 days (1,B) (Table 1) . 36, 56, 57 • Azithromycin in single-or multiple-dose regimens or shorter course of doxycycline (100 mg twice a day orally for 7-14 days) has also been proposed, but consistent and concluding evidence is lacking to currently recommend these drug regimens as first-line options (2,D). 58, 59 If alternative treatment regimens are used, it is advised to perform a test of cure (TOC) (2,D).
• There is no indication nor evidence that HIV co-infection requires a different therapeutic approach.
Which antibiotic should be used to treat asymptomatic LGV?
• Doxycycline 100 mg twice a day orally for 21 days is the first-line recommended therapy (1,C).
36,56,57
• There is some data on alternative (shorter) treatment regimens for asymptomatic LGV (2,D). 59 If alternative treatment regimens are used, it is advised to perform a TOC (2, D).
Alternative regimens to treat LGV
• Erythromycin (ethylsuccinate) 400 mg 4 times daily 21 days, orally (2,D).
• Many guidelines mention erythromycin as an alternative treatment option in patients with a contraindication to doxycycline, based on expert opinions. [31] [32] [33] However, no trials evaluating erythromycin in LGV treatment have been reported and high rates of gastrointestinal effects are described in patients treated with erythromycin for other indications. 60 Treatment success has been reported in a few cases with anorectal infections using moxifloxacin (2, D), 61, 62 ; however, great care should be undertaken before using the broad-spectrum moxifloxacin widely, because of its importance in the treatment of, for example, Mycoplasma genitalium infections. Treatment success has also been documented in small older trials for inguinal LGV using minocycline (2,D) 63, 64 and rifampicin (2,D). 65 Thus, it is suggested to only use moxifloxacin, minocycline or rifampicin if other options are unavailable.
Adjunctive therapy
• Apart from oral antibiotic therapy, fluctuant buboes should be drained via needle aspiration through healthy overlying skin (2,D). Repeat visits might be necessary to ensure reemerging buboes are drained.
• Surgical incision of buboes is not recommended due to potential complications such as chronic sinus formation (2, D).
• Patients with residual fibrotic lesions or fistulae do not benefit from further courses of antibiotics. Surgical repair, including reconstructive genital surgery, should be considered (2,D).
Partner notification and treatment
Partner notification should be initiated when the diagnosis is made. Sexual contacts within the last 3 months should be offered testing from all exposed sites for C. trachomatis/LGV and empiric treatment with doxycycline commenced until C. trachomatis/LGV has been excluded in the partner. It is not evident if alternative shorter course regimens are as effective in asymptomatic partners; case reports suggest treatment failure of contacts of LGV index patients treated with azithromycin 1 g single oral dose (2,D). 
Follow-up
All patients diagnosed with LGV should be followed up at the end of treatment:
• to ensure treatment compliance, assess side effects, and ensure resolution of symptoms and signs of infection (2,D);
• to check that adequate partner notification has been completed (2,D);
• to address any patient concerns (2,D); Lymphogranuloma venereum guideline 2019
• to arrange suitable follow-up testing for syphilis, gonorrhoea and blood-borne viruses including hepatitis B, C and HIV (2,D);
• Although one case of doxycycline failure in LGV has been reported, 61 a TOC for LGV is not considered necessary if the recommended 21-day course of doxycycline is completed (2,C). However, if alternative treatment regimens are used, it is advised to perform a TOC 4-6 weeks after the end of treatment (2,D).
Prevention/health promotion
Patients diagnosed with LGV should be counselled regarding prevention of other STIs including HIV and hepatitis C:
• Offer regular sexual health screening including HIV testing.
• Condom use should be demonstrated and promoted.
• Offer hepatitis A and B vaccination for MSM.
• HIV-negative patients should be advised of the availability of PrEP to prevent HIV infection.
• In particular, HIV-positive MSM should be made aware of recent trends in hepatitis C epidemiology and warned of the risks of unprotected anal sex, serosorting, recreational drug use [chemsex, Party and Play (PnP)] and mucosally traumatic sexual practices such as the use of toys and fisting. Enema use does not seem associated with STI infection. 66 It is prudent to advise against sharing any enema/ douching equipment and to wash equipment thoroughly after use. If patients engage in chemsex, associated problems should be addressed and referral to substance use care offered.
Notification of LGV cases
According to local, regional and national regulations, it might be required that LGV cases need to be reported to authorities. The European Centre for Disease Prevention and Control (ECDC) is responsible for the European Union/European Economic Area (EU/EEA)-wide surveillance of communicable diseases including LGV.
Auditable outcome measures (target 95% for all)
• All cases of suspected LGV should be subjected to appropriate laboratory investigations.
• All patients should be interviewed for the purpose of partner notification and this should be documented in the case notes. Sexual contacts within at least the last 3 months should be traced, tested and treated.
• In all patients, screening for concomitant STIs should be offered before starting therapy and after 3 months.
• Suspected or confirmed cases of LGV should be reported and relevant surveillance data collected according to local and national guidelines.
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